The uplifted FY26 outlook reflects a reversal on Q1 FY26, in which BD trimmed its outlook due to impacts from the sale of its ...

Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced in Q1 CY2026, with sales up 5.2% year on year ...

BD (Becton, Dickinson and Company), a leading global medical technology company, announced that Vitor Roque has been named ...

Moby Strategic Performance and Operational Drivers. Management attributed solid Q2 performance to broad-based executi ...

Thank you, Shawn, and good morning, everyone. Before turning to Q2 results, I wanted to take a moment to highlight this morning our announcement of Vitor Roque as CFO. As you know, Vitor has been ...

Waters Corp. and BD announced a definitive agreement July 14 to combine BD’s Biosciences & Diagnostic Solutions businesses with the Milford, Mass.-based company. The deal is structured as a ...

The deployment incorporates AI through the BD Pyxis Pro Dispensing Solution with Analytics in BD Incada.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

BD has become the subject of a lawsuit from Tela Bio, with the rival maker of surgical mesh implants saying the major medtech wielded its sector dominance to push competing products out of the hernia ...

The scientific-instrument company Waters will deepen its biological sciences footprint by merging with the biosciences and diagnostic solution business of Becton, Dickinson (BD). The companies value ...